Rick E. Winningham - 25 Feb 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TBPH
Reported as of: 25 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Mar 2022, 18:18:23 UTC
Prior SEC filing: 23 Feb 2022
Next SEC filing: 24 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 01 Mar 2022.

Key facts

This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Mar 2022, 18:18.

Change

Previous filing in this sequence was filed on 23 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +170,000
Change %: +13%
Price: $0.000000
Shares after: 1,449,300
Date: 25 Feb 2022
Ownership: Direct

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,567
Date: 25 Feb 2022
Ownership: By Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBPH transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +515,000
Change %
Price: $0.000000
Shares after: 515,000
Date: 25 Feb 2022
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 515,000
Exercise price: $10.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter.